Table 3.
Age Category | Chi-square test p-value |
|||||
---|---|---|---|---|---|---|
<2 years | 2–5 years | 5–10 years | 11–15 years | 16–18 years | ||
Ampicillin | 14 (30%) | 75 (53%) | 46 (38%) | 33 (35%) | 72 (39%) | 0.015 |
Amoxicillin-clavulanate* | 18 (56%) | 44 (66%) | 44 (59%) | 38 (62%) | 72 (66%) | 0.795 |
Cefazolin | 30 (64%) | 117 (82%) | 86 (72%) | 68 (74%) | 147 (81%) | 0.029 |
Cephalothin | 31 (67%) | 105 (74%) | 77 (64%) | 60 (65%) | 131 (72%) | 0.361 |
Ciprofloxacin | 35 (100%) | 86 (99%) | 55 (100%) | 47 (100%) | 118 (98%) | 0.707 |
Gentamicin | 56 (98%) | 151 (97%) | 128 (99%) | 92 (99%) | 176 (97%) | 0.486 |
Nitrofurantoin | 21 (45%) | 44 (31%) | 64 (53%) | 38 (41%) | 66 (36%) | 0.004 |
Tetracycline | 32 (70%) | 52 (37%) | 78 (65%) | 67 (73%) | 116 (64%) | <0.001 |
Tobramycin | 56 (98%) | 151 (97%) | 129 (99%) | 96 (100%) | 181 (98%) | 0.322 |
TMP/SMX | 46 (81%) | 116 (74%) | 102 (78%) | 89 (91%) | 172 (93%) | <0.001 |
TMP/SMX: trimethoprim/sulfamethoxazole
Susceptibility testing not routinely reported for ampicillin susceptible isolates